ArticleThe Pan African medical journal2025
Access to medicines for the management of asthma in Nigeria: is it getting worse?
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent inflation, economic instability, limited healthcare resources, and the withdrawal of major pharmaceutical companies from Nigeria have constrained access to affordable asthma medications. This commentary highlights the challenges faced by patients with asthma in obtaining essential medicines for symptom relief and control in Nigeria, while advocating for sustainable strategies to improve access across the population. Several barriers contribute to the unavailability of asthma medicines in pharmacies. Even when available, their costs remain prohibitive for most patients. To address this, medicine prices should be subsidised, local pharmaceutical manufacturers encouraged to produce essential asthma therapies, and health insurance schemes expanded to include and cover these vital medications. This could improve equitable access and outcomes for individuals living with asthma in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.